Don't assume that just because California has pushed back its pedigree/serialization compliance date back to 2015 that it doesn't matter anymore. It's still very relevant, says Pembroke Consulting's Adam Fein, and will likely serve as the model for inevitable federal regulations.
Pharmaceutical Manufacturing spoke with Fein recently about these issues and the cost of compliance--this podcast picks up in the middle of the conversation.
[Editor's Note: For regular and truly expert insight on the pharma supply chain, visit
Fein's Drug Channels blog.]
